Chemo patch for skin cancer shows promise in early trial
NCT ID NCT03646188
First seen Apr 28, 2026 · Last updated May 02, 2026 · Updated 2 times
Summary
This early-stage study tested a new way to deliver the chemotherapy drug doxorubicin directly into basal cell skin cancers using a dissolving microneedle patch. The goal was to find the safest dose and see if it could completely remove the cancer. The trial included 13 adults with small, untreated skin cancers, but was stopped early. Results focused on skin reactions and whether the cancer was fully cleared after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Center for Clinical and Cosmetic Research
Aventura, Florida, 33180, United States
Conditions
Explore the condition pages connected to this study.